Living with scleroderma? Learn about its impact on the lungs at our upcoming webinar. 🫁 Join us for a special ILD Day webinar in recognition of Interstitial Lung Disease (ILD)...
Read More
Registration opens soon for a special ILD-focused webinar, taking place on Tuesday, September 16, 2025, at 9:00 AM PT / 12:00 PM ET. Led by Dr. Toby Maher, Professor of...
Read More
Boehringer Ingelheim has announced that its Phase III FIBRONEER-ILD trial examining nerandomilast met its primary endpoint, measuring lung function through forced vital capacity (FVC) at 52 weeks. While nerandomilast remains...
Read More
We are excited to share that CONQUEST, a global platform clinical trial created by the Scleroderma Research Foundation, has opened 68 sites in 13 countries. Individuals with interstitial lung disease...
Read More
Groundbreaking clinical study recently launched to accelerate clinical development of new treatments for scleroderma Journal of Scleroderma and Related Disorders outlines protocol and rationale for two initial investigational drugs San...
Read More
SAN FRANCISCO, October 3, 2023 — The Scleroderma Research Foundation (SRF), the nation’s largest non-profit funder of scleroderma research, today announced that Boehringer Ingelheim, a leading research-driven biopharmaceutical company, will…
• Sanofi is inaugural partner • Initial focus on Interstitial Lung Disease Secondary to Scleroderma • SRF will submit and hold the IND as the trial Sponsor SAN FRANCISCO, August...
Read More
Today, the Scleroderma Research Foundation announces the launch of CONQUEST, a highly innovative platform clinical trial designed to rapidly advance promising treatments for scleroderma. Industry partner, Sanofi, will contribute the first experimental...
Read More
Did you know that approximately 15% of people living with scleroderma have Interstitial Lung Disease (ILD)? Next week, Wednesday, September 14 is National ILD Day. We're joining forces again with...
Read More
As we start 2022, thank you for inspiring all of us at the SRF to remain laser-focused on our mission—finding a cure for scleroderma. And thanks to the support of our…
